Abstract: The present invention relates to novel soluble liquid (SL) formulations comprising A) quinclorac ammonium salts of formula I wherein R1, R2, R3 and R4 are independently hydrogen or optionally substituted alkyl, and B) a solvents of formula IIa wherein R5 is alkyl; A is alkylene or oxyalkylene; and m is 0, 1, 2 or 3; and/or a solvent of formula IIb HO—B—OH??(IIb) wherein B is a straight-chain or branched alkylene or alkyleneoxyalkylene or alkyleneoxyalkyleneoxyalkylene.

Abstract: A precursor for a Nb3Sn superconductor wire to be manufactured by the internal diffusion method. The precursor includes Nb-based single core wires, Sn-based single core wires, and a cylindrical diffusion barrier made of Ta or Nb. Each Nb-based single core wire includes a Nb-based core coated with a Cu-based coating made of a Cu-based matrix. Each Sn-based single core wire includes a Sn-based core coated with a Cu-based coating made of a Cu-based matrix. The Nb-based single core wires and the Sn-based single core wires are regularly disposed in the diffusion barrier. The Nb-based single core wires includes at least two kinds of Nb-based single core wires having different Cu/Nb ratios and the Cu/Nb ratio is a cross sectional area ratio of the Cu-based coating to the Nb-based core.

Abstract: The present invention provides copolymers that facilitate nucleic acid analysis, compositions that comprise such copolymers, and methods for making or using such copolymers.

Abstract: Disclosed are compositions, kits, and methods for detecting, extracting, visualizing, and identifying a pathogenic protozoan. Quantitative real time polymerase chain reaction in connection with specifically designed oligonucleotide probes are used to detect a variety of pathogenic protozoans in patient samples.

Abstract: The invention relates to a method for modifying one or more peptide ligands, comprising polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of providing one or more peptide ligands, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more proteases; and sorting the ligands according to the extent of proteolytic cleavage.

Abstract: A composition includes a first probe and a first initiator bonded to the first probe. The first probe is capable of binding to an analyte and the first initiator is capable of initiating a controlled polymerization reaction. An associated kit, device, and method are provided.

Abstract: A composition includes a first probe, a first initiator component bonded to the first probe, a second probe, and a second initiator component bonded to the second probe. The first probe and the second probe are capable of binding to a single analyte, and the first initiator component and the second initiator component are capable of forming an initiator when present in proximity to each other and when the first probe and the second probe are bonded to the analyte. An associated kit, device, and method are provided.

Abstract: Peptides and polypeptides that elicit immunogenic responses in a mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7 are disclosed Immunogenic compositions including these peptides, and polypeptides are also provided. Compositions including these peptides and polypeptides with or without adjuvants are disclosed. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also disclosed. Methods of inhibiting infection by influenza, with or without cell entry, are also disclosed using these peptides and polypeptides.

Abstract: Provided is a surface having metal regions and an interstitial region having a composition that differs from the metal regions, wherein a continuous gel layer coats the surface across the metal regions and the interstitial regions. Nucleic acids or other analytes can be attached to the continuous gel layer such that a greater amount is attached over the metal regions than over the interstitial region. Also provided are methods for making such surfaces. Methods are also provided for making an array of nucleic acids or other analytes using such surfaces.

Abstract: A microarray is designed capture one or more molecules of interest at each of a plurality of sites on a substrate. The sites comprise base pads, such as polymer base pads, that promote the attachment of the molecules at the sites. The microarray may be made by one or more patterning techniques to create a layout of base pads in a desired pattern. Further, the microarrays may include features to encourage clonality at the sites.

Abstract: Formulation for a natural product as a replacement for the use of traditional acidic chemical stimulation methods for the emulsification, removal and release of paraffin and asphaltenes from low producing or pumped off wells and reservoirs with the use of traditional methodologies. Also a method of use of formulation for stimulating an oil well consisting of introducing into the wellbore a biodegradable, non-reactive fluid system containing a water-miscible fatty acid solvent, a solution of fatty acids, an amino alcohol, and at least one non-ionic surfactant. The fluid system may be further in the form of a nanoemulsion that is formed by combining a colloidal solution with one or more emulsifiers, an alcohol, and water. The fluid system may be used in well remediation and stimulation as well as additional, alternative applications such as the cleaning of surface and/or downhole equipment.

Abstract: Fiber bundles are prepared by affixing at least two fibers with a binding agent. The binding agent is designed such that the fiber bundles remain intact as the fiber bundles are mixed with and suspended in a fluid. After the fiber bundles exit the mixing apparatus, the binding agent degrades and releases the individual fibers. This allows higher concentrations of fibers to be added to fluids without fouling the mixing apparatus.

Abstract: Breaker nanoparticles may be added to gelled aqueous fluids where the gelled aqueous fluid may include an aqueous base fluid, e.g. a drilling fluid, gelled with at least one viscoelastic surfactant (VES) in an amount to increase the viscosity of the aqueous base fluid. The addition of the breaker nanoparticles may reduce the viscosity, or break the gel, of the gelled aqueous fluid by the direct or indirect action of the breaker nanoparticles. The breaker nanoparticles may be or include, but are not limited to inorganic semiconductor particles, organic semiconductor particles, and combinations thereof.

Abstract: A functional fluid comprising a major amount of an oil of lubricating viscosity, and at least about 0.05 wt-% glycerol. A method of preparing a functional fluid comprising adding glycerol to a functional fluid, wherein the glycerol is not glycerol monooleate. A method of preparing an additive concentrate comprising adding glycerol to a diluent oil wherein the concentrate contains from about 1% to about 99% by weight of said diluent. A method of reducing wear comprising contacting a metal surface with a functional fluid comprising a major amount of an oil of lubricating viscosity and at least about 0.05 wt-% glycerol.

Abstract: The disclosed invention relates to a composition comprising a grafted polymer. The polymer comprises a backbone with at least one olefin block and at least one vinyl aromatic block. The polymer is grafted with a pendant carbonyl containing group, the grafting being conducted by halogenating the vinyl aromatic carbon of the vinyl aromatic block and then grafting a carboxylic acid or derivative thereof on the halogenated vinyl aromatic carbon in the presence of an activating agent. The carbonyl containing-group is optionally substituted to provide ester, imide and/or amide functionality. The grafted polymer is useful as a dispersant viscosity modifier in lubricating compositions such as engine oils.

Abstract: A lubricating base oil contains: an overbased calcium sulfonate having a different base number provided such that a total base number is in a range of 280 to 500 mgKOH/g and a calcium concentration in a total amount is in a range of 280 to 3000 mass ppm (in terms of calcium); and orthophosphates that is at least one selected from phosphates and acid phosphates and provided such that a phosphorus concentration is 50 mass ppm or more. A high friction coefficient of 0.11 or more and a favorable wear resistance of a specific wear rate of less than 2.0×10?8 mm3/Nm are obtained, thereby reliably providing a high power transmission capacity for a long period of time, particularly in a belt-type continuously variable transmission equipped with a metallic belt.

Abstract: A carboxylate detergent prepared by the process comprising (a) alkylating a hydroxyaromatic compound with at least one alpha olefin oligomer, derived from C8 to C20 alpha olefins, to thereby produce an alkylhydroxyaromatic compound, and wherein at least 90% of the molecules in the alkylhydroxyaromatic compound have the alkyl group attached at the 4-position or higher from the terminus of the longest chain of the alkyl group, and further wherein the alkyl group comprises at least one hydrocarbon tail of at least 7 carbons; (b) neutralizing the resulting alkylated hydroxyaromatic compound with an alkali metal base; (c) carbonating the alkali metal salt from step (b) with carbon dioxide; (d) acidifying the salt produced in step (c); and (e) overbasing the resulting alkylated hydroxyaromatic carboxylic acid.

Abstract: A lubricant composition, additive concentrate, and method for lubricating an engine. The crankcase lubricant has less than 30 weight percent of a relatively low Noack volatility base oil and a viscosity additive. The viscosity additive has a minor effective amount of sacrificial polymeric viscosity index improver having a shear stability index (SSI) of greater than about 45 and a major amount of a viscosity index improver having an SSI of less than about 26. The minor amount of sacrificial viscosity index improver additive is effective to provide a lubricant composition having a ratio of absolute viscosity increase at 40° C. to an absolute viscosity increase at 40° C. of an RL 216 reference oil of less than about 0.8.

Abstract: A composition is provided for use as a friction modifier for an automatic transmission, comprising a long chain hydrocarbyl amine having one or two additional groups on one or two different amine nitrogen atom thereof of the structure —R3-C(=0)X(R4)c. R3 is an alkylene group or a group comprising a group of 1-4 carbon atoms or a chain of 2 to 9 carbon atoms interrupted by one or two nitrogen or oxygen atoms within the chain; X is nitrogen or oxygen, and R4 is a long chain hydrocarbyl group, or H, or —R3-NHR5. The compound does not contain a primary amino group.

Abstract: Polymeric additives are disclosed for compressor lubricants which can reduce the tendency of the lubricant to become entrained in compressed gases and be carried forward as fine dispersed droplets in compressed gas systems such as compressed air, natural gas, and compression refrigeration systems.

Abstract: Cleaning and disinfecting compositions containing one or more “green” surfactants are disclosed. The compositions may be present as micro-emulsions that generally include green disinfecting agents, green surfactants, and water. The composition may also contain other green ingredients such as linkers, pH adjusting agents, natural fragrances, natural insecticides, and other natural organic actives such as natural oils. The composition may be used as a green cleaning and disinfecting composition with performance comparable or superior to conventional cleaning and disinfecting products with less desirable ecological profiles.

Abstract: An aqueous and liquid cleansing composition comprises a fatty acid soap, a salt of a lauryl ether sulfate surfactant that is present in an amount that is at least 50% of the weight of the fatty acid soap, a betaine surfactant that is present in an amount that is at least 23% of the weight of the fatty acid soap, and at least 0.05% by weight of the composition of triclocarban. The lauryl ether sulfate and betaine surfactant in the specified amount in relation to the fatty acid soap amount keep the triclocarban from precipitating out of the composition.

Abstract: Concentrated liquid cleaning fluid compositions for hard surface cleaning which are particularly suited for storage and dispensing from water-dissolvable plastic pouches. In use the pouches are placed in water whereupon the plastic pouch dissolves allowing the concentrated composition to become diluted in the water to provide a cleaner. The concentrated cleaning composition has good stability and does not affect the plastic or rate of dissolution of the pouch, and allows use of a variety of colorants and fragrances with a base product formulation. The formulation includes a linear alkyl benzene sulfonic acid (LABSA), a nonionic ethoxylated alcohol surfactant, and an alkanol amine or alkyl amine capable of reacting with the LABSA so that the sulfonic group is added to the amine.

Abstract: A novel method of producing soaps from organic residues, in which otherwise valueless organic residues are saponified, is disclosed. The method comprises steps of (a) preparing a solution of a base in water; (b) reacting said solution with stearic acid; (c) adding glycerol; (d) adding a borate; (e) adding a surface-active agent; (f) dispersing an organic residue within the mixture; and (g) reacting said organic residue until a homogeneous soap composition is obtained. A novel soap made by this process is also disclosed.

Abstract: Provided are compositions comprising one or more compounds having a structure comprising a node structure with from four to twelve carbon atoms, one or more (poly)glyceryl groups, and one or more hydrophobic moieties, wherein each of the one or more (poly)glyceryl groups is linked to the node structure by a first primary linking group, the one or more hydrophobic moieties are each independently linked either to the node structure by a primary linking group or to one of the (poly)glyceryl groups by a secondary linking group, and wherein the polyglyceryl thickener has an average degree of glyceryl polymerization of from greater than 3 to less than about 11 and an average number of hydrophobic groups per primary linking group of about 0.35 or greater. Also provided are polyglyceryl compounds, compositions comprising water, a surfactant, and a polyglyceryl thickener, as well as, methods of making polyglyceryl compounds and compositions of the present invention.

Abstract: The present invention provides the softener composition containing the specific quaternary ammonium salts (I) and (II) each having a bis(polyalkoxyalkanol) structure, represented by the formulae (I) and (II) respectively, at a weight ratio of (I):(II) of 50.1:49.9 to 99.99:0.01.

Abstract: A continuous process of making a fabric softener composition comprising di(C6-C14)alkyl di(C1-C4 alkyl and/or hydroxyalkyl) quaternary and perfume, and a fabric softener composition obtained by the continuous process. The fabric softener composition obtained by the continuous process demonstrates a stable viscosity, especially while being stored for a prolonged period of time.

Abstract: The present invention relates to a process for producing perfume-containing microcapsules having both an aqueous inner phase and an oily inner phase, which can be used in home or personal care products, as well as to the process for producing these microcapsules and the consumer products containing them.

Abstract: The present invention relates to a stabilizer composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabilizer composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabilizer composition with a biological molecule and/or a micro-organism; to the use of such a stabilizer composition, and of vaccines prepared therewith.

Abstract: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.

Abstract: Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract: The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing activity or cancer growth suppressing activity have been found. Furthermore, it has been found that these metastin derivatives exhibit effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc., which are wholly different from the effects heretofore known.

Abstract: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.

Abstract: The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use.

Abstract: Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—RA [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and RA represents, e.g., the formula —X1—Ar1—X2—Y—X3—Ar2 (wherein X1, X2, and X3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N?, ?N—, —NR1—, —O—, etc.; Y represents —NR2CO— or —CONR2— (wherein R2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.

Abstract: An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumors over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry.

Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: Methods and compositions for treating an iron disorder in a patient are presented, including methods for delivering a therapeutically effective amount of iron to the brain. Iron disorders that may be treated by these methods include iron deficiency disorders and iron overload disorders. A recombinant yeast expressing human H-ferritin and a composition for treating an iron disorder comprising this recombinant yeast are also presented.

Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.

Abstract: Modified human growth hormone polypeptides and uses thereof are provided.

Abstract: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.

Abstract: The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.

Abstract: A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a biocompatible material, a liquid carrier, and a gas. The container has an internal pressure of greater than 1 atm and less than 250 atm, and includes a valve and a nozzle for releasing from the nozzle a foam formed of the composition upon opening the valve. Methods of producing and applying the biocompatible material are also disclosed.

Abstract: The described invention relates to the use of the TAT-BH4 peptide for treating or preventing the progression of ALS. The methods include, postponing the appearance of symptoms and improving motor performance and survival in ALS. Methods are also provided, wherein the TAT-BH4 peptide is in a composition further comprising a pharmaceutically acceptable excipient.

Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.

Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.

Abstract: The present invention relates to therapeutic uses of soluble alpha-Klotho.

Abstract: Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against ?IIb?3 integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to ?IIb?3 integrin or to both ?IIb?3 and ?V?3 integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for ?IIb?3 integrin.

Abstract: A method for promoting oral hygiene that treats mature biofilms comprises the step of applying the antimicrobial peptide KSL and a surface active agent to the oral environment of applying KSL after mechanical disruption of the biofilm. An antiplaque chewing gum comprising KSL provides a sustained release oral hygiene treatment.